CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 细胞治疗的门诊给药：面向社区中心的重点综述与实施建议
英文原题：Outpatient administration of CAR T-cell therapy: a focused review with recommendations for implementation in community based centers.
查看英文原题
Outpatient administration of CAR T-cell therapy: a focused review with recommendations for implementation in community based centers.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CAR-T 细胞疗法改变了血液系统恶性肿瘤的治疗格局，在复发/难治性（R/R）疾病患者中疗效较高，而这类患者在 CAR-T 时代之前预后较差。由于存在细胞因子释放综合征（CRS）和免疫效应细胞相关神经毒性综合征（ICANS）风险，此类疗法通常在住院环境中实施。不过，出于多方面考虑，人们对转向门诊给药的兴趣日益增加。本文回顾了 CD19 和 BCMA 靶向 CAR-T 细胞疗法门诊给药的安全性和可行性证据，并重点讨论在社区医疗中心实施门诊 CAR-T 项目。
展开英文摘要原文
Chimeric Antigen Receptor T-cell (CAR-T) therapy has transformed the treatment landscape for hematological malignancies, showing high efficacy in patients with relapsed or refractory (R/R) disease and otherwise poor prognosis in the pre-CAR-T era. These therapies have been usually administered in the inpatient setting due to the risk of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).
However, there is a growing interest in the transition to outpatient administration due to multiple reasons.
We review available evidence regarding safety and feasibility of outpatient administration of CD19 targeted and BCMA targeted CAR T-cell therapy with an emphasis on the implementation of outpatient CAR-T programs in community-based centers.
论文信息
- 作者
- Perez A、Al Sagheer T、Nahas GR、Linhares YPL
- 单位
- Miami Cancer Institute, Baptist Hospital of Miami, Miami, FL, United States.United States
- 文献类型
- 综述
- 期刊
- Frontiers in immunology2024
- 原文标识
- PubMed 38779668 · DOI 10.3389/fimmu.2024.1412002
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →